Sage triggers another burst of investor enthusiasm as oral depression drug scores in PhII
Sage Therapeutics shares are once again rocketing up this morning, this time based on positive results from a small Phase II study of an oral …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
